Myriad Genetics develops and commercializes molecular diagnostic tests that assess genetic risk and guide treatment decisions, best known for hereditary cancer testing including BRCA-related assays. Its portfolio spans oncology, women's health, and mental health pharmacogenetics, using gene-panel and biomarker technologies to inform screening and therapy choice. Customers include physicians, hospitals, and health systems that order lab-based genetic and companion diagnostic testing.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 195.9 | — | -0.1 | — |
| Q2 2025 | 213.1 | — | -330.5 | — |
| Q3 2025 | 205.7 | — | -27.4 | — |
| Q4 2025 | 209.8 | — | -7.9 | — |
| Q1 2026 | 200.4 | 2.3% | -34.1 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Parke Bancorp, Inc. (PKBK), Northeast Community Bancorp, Inc. (NECB), Scribe Therapeutics Inc. (SCTX), Alpha Teknova, Inc. (TKNO), MVB Financial Corp. (MVBF), Yorkville International Capital Corp. (YICC)